North America injectors Market is expected to reach US$ 5767.51 Mn by 2027

On-body injectors segment by type is estimated to lead the market growth during the forecast period

According to The Insight Partners market research study of “North America wearable injectors Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type, Application and End User,” the North America wearable injectors Market is projected to reach US$ 5767.51 million by 2027 from US$ 2370.52 million in 2019. The market is estimated to grow at CAGR of 11.9% from 2020 to 2027. The report highlights trends prevailing in the North America wearable injectors market and the factors driving market along with those that act as hindrances.

Based on type, the North America wearable injectors Market is further segmented into on-body injectors and off-body injectors

The on-body injectors segment held a larger share of the market in 2019. The growth of the segment was determined due to the benefits offered by on-body injectors such as comfort, water resistance, flexible dosing, and automatic warming of refrigerated drug and easy to use.

An on-body injector is a wearable injection device. These devices are becoming popular with cancer patients in the wearable injectors market. Once the device is implemented to the stomach or arm, it slowly delivers the medication over some time. This allows patients to be treated at home without exposure to other infections during treatment. The convenience is making the wearable injectors one of the most in-demand in the forecast period.

As the trend of patient care from the clinic to the home continues and a growing number of parenteral biologic products are developed for chronic conditions, there is a greater need for devices that allow patients or non-clinicians to administer injectable medications safely and effectively. In current years, there has been a notable interest in on-body injectors from pharmaceutical companies developing biosimilars. Moreover, many high-volume dosages are being given with the help of body injectors. For instance, Amgen’s Neulasta (peg filgrastim) is delivered as a single 0.6 mL subcutaneous injection one day after a course of chemotherapy to prevent neutropenia and therefore reduce the risk of infection. Amgen’s Onpro on-body injector device is used as a drug delivery device for Neulasta

North America wearable injectors Market is expected to grow owing to factors such as increasing chronic diseases prevalence, technological advancements and design development, and conventional drug delivery system. However, the market is likely to have negative impact due to preference of alternative drug delivery.

BD, CeQur SA, Debiotech S.A., E3D Elcam Drug Delivery Devices, Insulet Corporation, Gerresheimer AG, Tandem Diabetes Care Inc, Zealand Pharma A/S, West Pharmaceutical Services, Inc, Ypsomed AG, Medtronic, Amgen, Inc. Are among the leading companies operating in the North America wearable injectors Market.  

North America Wearable injectors  Market, By Country, 2019 (% share)

---

North America injectors Market Regional Overview by 2027

Download Free Sample

---

North America injectors Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type (On-body Injectors and Off-body Injectors); Application (Oncology, Diabetes, Autoimmune Disease, Cardiovascular Disease, Other Applications), End User (Homecare Setting, Hospitals and Clinics, Other End Users) and Geography

The report segments North America wearable injectors market as follows

By Type

• On-body Injectors
• Off-body Injectors

By Application

• Diabetes
• Oncology
• Cardiovascular Disease
• Autoimmune Disease
• Other Applications

By End User

• Hospitals and Clinics
• Homecare Setting
• Other End User

By Country

• US
• Canada
• Mexico